FAP and squamous cell carcinoma: These findings suggest that [177Lu]Lu -FAP-2286 RPT is a promising approach for relatively few side effects.101 In 2022, Rao et al. reported that [177Lu]Lu-FAP-2286 was administered to a patient with systemic metastases from squamous cell carcinoma of the right lung.